Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics is positioned attractively because Auvelity is compounding rapid commercial momentum, with 2Q26 net product revenue up 46% year over year and 2Q26 sales of $180.3M, while total prescriptions reached about 266,000 and new-to-brand scripts rose 26% sequentially. The recent approval in Alzheimer’s disease agitation materially expands the addressable market into a large, underserved population, with near-universal Medicare Part D access and more than 85% of covered lives lacking prior authorization, supporting faster uptake and low incremental launch cost. Beyond Auvelity, the company has a de-risked CNS pipeline and existing commercial infrastructure across multiple products, with key readouts expected over the next 12-18 months and cash flow positivity modeled for 2027E.

Axsome Therapeutics is fundamentally challenged by heavy dependence on Auvelity while its broader pipeline faces slow commercialization, payer friction, and entrenched competition from cheap generics and better-established branded alternatives. Sunosi showed only $33.8M in 2Q26 sales, flat sequentially despite +10% script growth, and Symbravo generated just $2.3M in 2Q26 with net revenue per script shrinking about 75%, underscoring weak pricing power and access constraints. Added to that are long-dated catalyst risk, IRA exposure starting in 2032, and financing and dilution risk inherent to a clinical-stage biotech, which together make durable fundamental upside difficult to underwrite.